Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Acyclic nitrogen double bonded to acyclic nitrogen – acyclic...
Reexamination Certificate
2007-01-02
2007-01-02
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Acyclic nitrogen double bonded to acyclic nitrogen, acyclic...
C514S045000, C514S047000, C514S046000, C514S048000, C514S263400, C514S263370, C514S895000, C514S262100, C536S025320, C536S022100, C536S025310, C536S023100, C562S573000, C435S069100
Reexamination Certificate
active
10258810
ABSTRACT:
The present invention relates to the use of an inhibitor of CTP synthetase, such as a glutamine analogue, and a substance capable of suppressing toxic effects thereof in vivo, in the manufacture of a medicament for the treatment of a disease caused by a parasitic protozoa. More specifically, said substance capable of suppressing toxic effects may be a nucleobase, such as a purine base or a nucleoside, while the glutamine analogue advantageously is 6-diazo-5-oxo-L-norleucine (DON). The invention also relates to a pharmaceutical composition as such for the treatment and/or prevention of a disease caused by a parasitic protozoa, wherein the disease is selected from the group consisting of malaria, leishmaniasis and trypanosomiasis, e.g. American trypanosomiasis (Chaga's disease), or African trypanosomiasis (African sleeping sickness).
REFERENCES:
patent: 5180714 (1993-01-01), Sufrin et al.
patent: 5776718 (1998-07-01), Palmer et al.
patent: 6159953 (2000-12-01), Rathod
patent: 6242428 (2001-06-01), Weis et al.
patent: 98/31375 (1998-07-01), None
Queen et al. “In vitro susceptibilities of Plasmodium falciparum to compounds which inhibit nucleotide metabolism.” Antimicrob Agents and Chemotherapy, Jul. 1990, 34(7), pp. 1393-1398.
Mukherjee et al. “Acivicn: A highly active potential chemotherapeutic agent against visceral leishmaniasis.” Biochemical and Biophysical Research Communications, vol. 170, No. 2, pp. 426-432, 1990.
Tanmoy Mukherjee et al, “Acivicin: A Highly Active Potential Chemotherapeutic Agent Against Visceral Leishmaniasis,” Biochemical and Biophysical Research Communications, vol. 170, No. 2, pp. 426-432, 1990.
Takashi Aoki et al, “Quantitative Determination of Trypanosoma Cruzi Growth inside Host Cells In Vitro and Effect of Allopurinol,” Purine and Pyrimidine Metabolism in Man VIII, pp. 499-502, 1994.
Kenneth E. Kinnamon et al, “Activity of Anticancer Compounds Against Trypanosoma Cruzi-Infected Mice,” Am. J. Trop. Med. Hyg., vol. 58, No. 6, pp. 804-806, 1998.
Kim E. Nichols et al, “Monocytoid Differentiation of Freshly Isolated Human Myeloid Leukemia Cells and HL-60 Cells Induced by the Glutamine Antagonist Acivicin,” Blood, vol. 74, No. 5, pp. 1728-1737, 1989.
Hofer Anders
Thelander Lars
Buchanan & Ingersoll & Rooney PC
Jiang Shaojia Anna
Khare Devesh
LandOfFree
Medicament for the treatment of diseases caused by parasitic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicament for the treatment of diseases caused by parasitic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicament for the treatment of diseases caused by parasitic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3764683